I honestly do learn something about the markets every day. I am not a Unilever (ULVR) shareholder but Domestos, Lipton, Hellmann’s and Magnum are far from disastrous brands. The attempt to buy the GlaxoSmithKline (GSK) consumer business a few months ago failed miserably though and has helped dump the Unilever share price about 18% over the last year at the close yesterday. But why is the stock up 6% today?
GlaxoSmithKline (GSK) has announced its first quarter of the year results and that it reconfirms its full-year 2022 guidance. We are well ahead on this share tip where we are also drinking our own medicine so what to do now?
I will have a listen later to the quarterly call from GlaxoSmithKline (GSK) following its first quarter numbers today. The numbers were fine and specifically mentioned the good performance of its pharmaceutical business ahead of the proposed demerger in July. I wrote about all this a couple of months ago and my advice remains to stay a holder here and make a call whether to retain one or both on the demerger in a few months time. If only all investments were as straightforward as the last 15 months in GlaxoSmithKline. And talking about more complex investments brings us to WH Smith (SMWH)...
Hello Share Tempters. There are two very big British pharmas you could invest in. A long time ago I chose GlaxoSmithKline (GSK), rather than AstraZeneca (AZN). I sometimes regret that choice as AstraZeneca seems to have been the more dynamic company, including with a Covid vaccine for example. But I would not swap holdings now, as I think things are happening at GSK that could improve its share price.
If you are a GlaxoSmithKline (GSK) investor, you may have noted last week that the FTSE-100 company observed the new name for its consumer health business ‘Haleon’ is from “Hale” (meaning in good health) and “Leon” (which it claimed was associated with strength) and declared it was to be pronounced “Hay-Lee-On”. Enjoy mispronouncing that! Of course the urban dictionary’s definition is a little bit alternative to this… So should GlaxoSmithKline’s shareholders be excited or concerned about July’s upcoming business split of the consumer health and core pharmaceutical business?
Last October I observed that Reckitt Benckiser (RKT) ‘without working hard offers the scope for a £60-70 share price plus picking up a dividend’. In short a holding in the ‘home to the world’s best loved and trusted hygiene, health and nutrition brands’ group theoretically for FY22 is probably over ten times more interesting than government bonds or money in the bank. How many times a month do you – or someone in your household – use Finish, Dettol, Air Wick, Nurofen, Vanish, Harpic, Calgon or Durex products? My guess is more than once. So what about the shares today post the group’s full year numbers publication?
I am looking forward to the GlaxoSmithKline (GSK) conference call later today. Whilst technically it is focused on the full year 2021 numbers out earlier today (which showed rising sales and falling profits), far more important is the confirmation that it is ‘on track to demerge a new world-leading Consumer Healthcare business mid-2022’. Last month I was amused by the (ultimately unsuccessful) partial bid approach by Unilever (ULVR) but my instinct is that the Pharmaceutical / Vaccines business is still underappreciated going forward. I was certainly pleased to see the ‘pipeline of 21 vaccines and 43 medicines’ angles and I do wonder – when the business split occurs in a few months time – whether not only retaining but adding to this part of the business. Something to be more thoughtful about later this year whilst, despite the excellent total return performance over the last year, I remain a strong HOLDer. So whilst I continue to hang onto my GlaxoSmithKline shares…what do I make of today’s interim results announcement from FTSE 100 housebuilder Barratt Developments (BDEV)?…
It was a busy last week and it is going to be a busy next week too. Such is this time of the year. It’s all good fun. Particularly entertaining – no doubt – will be the conference calls after full year updates from GlaxoSmithKline (GSK) and Unilever (ULVR). Sensibly the former is splitting up its business, whilst the latter really should be considering it a bit more. It will be enjoyable to listen to and react to (after all I own a bunch of shares in GlaxoSmithKline). But today I wanted to talk about Rio Tinto (RIO)…
I see Emma Walmsley – the current (but surely not for much longer) CEO of GlaxoSmithKline (GSK) – is very excited this morning, after the company announced hiring a new Chief Scientific Officer designate who will take the full job in August. I do agree with Emma that the appointment is positive and important, but I do wonder whether there will be also be a newly announced Glaxo CEO come August, irrespective of the company’s big intellectual and R&D push over the next few years. Even if Glaxo shares are back below 17 quid, you know my continuing positive thoughts as mentioned a few days ago HERE. Meanwhile, let’s talk about Burberry (BRBY).
Hello Share Shovers. You’ll either love this possible takeover – or hate it. The owner of Marmite is rumoured to very much want to snaffle the giant consumer arm of GlaxoSmithKline (GSK). And Unilever (ULVR) actually made a £50 billion approach. This was turned down as being too low. As an owner of GSK shares, I agree that it wasn’t an enticing proposition and I expect a bigger one to come.
I was already excited about the upcoming week, predominately because a bunch of interesting companies are giving us an update on Monday, Tuesday, Wednesday, Thursday, and Friday. So maybe an existing holding does well or maybe I get an opportunity to consider a new angle. One stock I am going to be watching closely on Monday morning is GlaxoSmithKline (GSK) as I read that ‘Unilever(ULVR) makes £50 billion bid for GSK’s consumer business’.
Markets might be a bit volatile today but such is life in the investment world. Anyhow, some good news for us current GlaxoSmithKline (GSK) shareholders as the company has ‘announced that Sir Dave Lewis has been appointed as Non-Executive Chair Designate of the new Consumer Healthcare company which will result from the proposed demerger from GSK in 2022…his appointment will take effect from 1st January 2022’. Good news as Dave Lewis was a legend over his time at Tesco (TSCO), a super successful turnaround he exited as CEO last year. It is always smart to exit stage left when the crowd is asking for more, and I am not surprised too he has taken a Chair role rather than a CEO one.
Hello, Share Chasers. There may be glittering prizes around for some folks holding some shares. I refer to the craze among foreign private equity outfits for eyeing up British companies, some of which are household names. A reasonable stratagem then is to buy shares in likely targets. But what are the best bets?
GlaxoSmithKline (GSK) has announced second quarter of the year results, including stating “strong commercial execution” and “we are likely to deliver full-year Adjusted EPS towards the better end of our guidance range”. So where now for the shares?, with they currently having responded back up to 1400p.
FTSE-100 pharma and healthcare company GlaxoSmithKline (GSK) is currently engaged in somewhat of a battle with well known activist investor Elliott Advisors. However, that is about the level of change as change is coming and Elliott is only involved as it “believes GSK has a substantial value creation opportunity – 45% upside in its share price – ahead of Consumer Health separation and greater beyond”. We concur that there is an attractive value creation opportunity here…
Joshua and I are about to have pancakes and a swim and then set out on the next leg of our road trip. A few photos from yesterday’s tearful encounters are HERE. In today’s podcast, I look at the smears that establishment folk like Alex Brummer are using to defend an establishment woman who has failed to deliver, the grotesquely overpaid CEO of GlaxoSmithKline (GSK) Emma Walmsley. I want her to pack her bags too and explain why she should.
Entering a new month, a new quarter and a new half-year is always a busy moment. However rather than rambling on about whether the markets can push on further from the gains of the first six months of 2021, let’s look at a few stocks that have said something interesting this morning. After all it patently is an active and not a passive stock market out there.
In today’s bearcast, I consider Verditek (VDTK), GlaxoSmithKline (GSK), Sosandar (oink, oink), First Property (FPO), Remote Monitored Systems (RMS) and MyHealthChecked (MHC).
Earlier this year – a week or two after I published an article on the British multinational pharmaceutical company GlaxoSmithKline (GSK) HERE, I bought shares in the FTSE 100 giant for the first time in well over a decade. It has worked out pretty well so far, but the story is certainly evolving because
as I noted here in early May ‘GlaxoSmithKline is fortunately about so much more than the current CEO’. I am sure you have heard about the ‘strategic overhaul of GlaxoSmithKline by Dame Emma Walmsley’ which was announced yesterday.
I turned positive – for the first time in years and years – on GlaxoSmithKline (GSK) shares back in February here. I noted back then that my optimism was based on much more than cheapish EV:ebit ratios and alright free cash flow generation (and the dividend paid). As I noted again here a few weeks back, “Hedge fund Elliott builds up multibillion-pound stake in GSK” because the anticipation that GlaxoSmithKline will split out some of its business is set to happen over the next year and this will create extra value.
Goodness it has been busy over the last couple of days in the corporate earnings world! Yesterday I really wanted to get an opportunity to make more comments about the condom business of Reckitt (RKT), which I positively wrote up here back in February. Anyhow for various reasons or another – absolutely nothing to do with condoms! – I never got around to it. However, despite the positive share price move since February, I still remain a buyer with an over 7500p target.
First I see that GlaxoSmithKline (GSK) shares were nicely firm yesterday. As I noted here back in mid-February I could see an opportunity to buy the shares…which I did later on that month. Yesterday’s move was driven by an article – planted in the FT – which noted that “Hedge fund Elliott builds up multibillion-pound stake in GSK…Activist group’s investment comes as UK drugmaker’s performance lags rivals”.
Hello, Share Tasters. It’s been a while since I’ve looked at GlaxoSmithKline (GSK). It’s the big British rival of AstraZeneca (AZN). Though it’s lost out in the publicity stakes associated with a covid vaccine, Glaxo should still benefit from a heightened interest in all things medical.
I have not been a fan of GlaxoSmithKline (GSK) shares for a long time now but if you pick up its chart today, you will see the stock kicking around at a new five year low. So what to think about a name that used to be a FTSE 100 favourite…and is even actively trying to finalise a Covid-19 vaccine product?
Hello Share Chasers. Many of us will be trying out short-term plays on speculative shares in these volatile days. With shares up and down a lot, you may even be tempted into a bit of day trading. However, my 24-hour trades nearly always become long-term investments as the hoped for daily hike hardly ever happens. Not to me anyway. So let’s look at a share which, if held long enough, could be a strong winner...
Hello, Share Seekers. I’ve been l reviewing my general predictions for various sectors over the last three years. It amazes me how many forecasts proved right. Not sadly for the right reasons, though. Because nobody foresaw that the world would suffer the pandemic. However, perhaps our subconscious was warning us. It may more to do with correct share-picking than we tend to think.
I learnt something new this weekend: AstraZeneca (AZN) is the biggest company on the UK market in terms of capitalisation, having doubled it in the last three-and-a-half years or so. So well done to it, especially as a number of years back - in its shoes - I would have bitten off the corporate approach made by Pfizer and sold the company.
Hello, Share Breakers. As I’ve suggested before, pharmaceutical companies, both gigantic and small, could benefit from the heightened interest in all health matters. And I would guess that the one that comes up with a vaccine for COVID-19 might do even better. So which companies are looking for a vaccine?...
Hello, Share Trawlers. Here’s another suggestion for your plans to buy more shares once the virus is on its way out. Today’s choice is big pharma companies, like GlaxoSmithKline (GSK) and AstraZeneca (AZN). There are also a few foreign listed companies, like Roche and Johnson & Johnson, that you might consider...
Yet the one or two deaths it brought to Britons become headline news. Can you possibly imagine every flu death being treated in the same way? Meanwhile, there are signs of that China, the source of the outbreak, is seeing a drying up of cases. That’s surely likely to happen everywhere.
Assuming that you aren’t just going to move entirely to cash and wait for the markets to bottom and show signs of a rebound before buying anything, there are still some options for shares to hold whilst you ride out the storm.
Hello Share Trackers. There are some share analysts who've been trying to convince us over the last few years or so that our shares are cruising for a bruising. Do they really expect us to sell all we have and lurch into cash? My holding in Ceres Power (CWR) to take just one of a miriad examples shows that the sell-all view could be wrong. On the back of no news as far as I can see, this wonder share has been rising one or two perent daily for a long time now. And last week the share increased itn value by nearly a fifth...
Hello, Share Folks. Allow me to suggest that there’s a compelling case, getting stronger by the week, for investing in pharmaceutical companies. For the more cautious among us, this will be the giants, like GlaxoSmithKline (GSK) and AstraZeneca (AZN). Share prices in both are already buoyant and the divis are handy. But the more speculative investor will be trying for the huge rewards that a pharma mini can achieve if it strikes lucky with a drug it’s researching.
Hello, Share Dibbers. The jumbo pharma GlaxoSmithKline (GSK) is undergoing changes. And if you think the company is making the right decisions, then then you might consider a closer look. The City has been pleased with the latest quarter results and though my own holding has not risen much over the years, perhaps that could change now...
Hello Share Tasters. Having scoured my sources, I cannot discern any obvious new recommendations for your further researches. So perhaps it would be more useful to point your way to a couple of my Footsie favourites which are bucking the downward trend at the moment. While reminding you of that very useful adage 'the trend is your friend'...
I asked back in January whether GlaxoSmithKline (GSK) wanted a 'yes man' new chair in order to push through the CEO's plan to split the business (and pursue some expensive-sounding deals on the consumer side). The share has pushed up a pound or so since then, so the lack of clarity on this question has not been a huge issue overhanging the stock but we have a little bit more insight on this issue - with reports that the company is close to hiring Jonathan Symonds, a real pharma sector insider with experience at AstraZeneca (AZN) and Novartis among others…
Hello, Share Twizzlers. This old punter generally finds that if the Footsie is rising in spectacular fashion, as it is now, then we might as well put penny shares on the back burner. That’s because most traders realise you don't have to attach big risk to your money if you can still make dosh from the (usually) safer jumbos...
Hello Share Peekers. A Footsie jumbo which I have shares in, but rarely write about, is GlaxoSmithKline (GSK).To give you an idea of its size, it’s the fourth biggest outfit in the Footsie. And while it's true the big fish can flounder, like the former British Energy, for example, we can hope for a measure of security not inherent in smaller companies.
Travel operators TUI AG (TUI) and Thomas Cook Group (TCG) both featured in the top five most frequently tipped companies over the last seven days in a busy week for trading updates. Homebuilders Barratt Developments (BDEV) and RedRow (RDW) also received an influx of tips after both released interim results, while there was increased tip activity for GlaxoSmithKline (GSK) and Smith & Nephew (SN.).
Hello Share Trudgers. Though treading in my erudite colleague Chris Bailey’s shoes, I thought it might be useful to have another take on GlaxoSmithKline (GSK) This giant pharma is a big part of my ‘safer’ Footsie portfolio (I put safer in quotes as some of my biggest losses ever have been members of the big 100 club)...
Hello, Share Swappers. As you know, Big Donald’s stand-off with opposing politicians has led to the curtailment of government activities in Washington. You might not be aware that some British firms are affected by this curious situation. For example, those federal officials who give go-aheads to pharmaceutical companies have not been able to act as speedily as they’d like to...
Hello, Share Whackers. My more inspirational Shareprophets colleague Chris Bailey has already posted on an exciting development for GlaxoSmithKline (GSK). As this is a share I’ve also pushed for some years, allow me to add my own humble thoughts...
Back in the day, I used to be an institutional fund manager and did go on a number of brokerage lunches at around this time of year. The essential underlying aim of these lunches did not change for years: a thank you for business given during the year...and a pitch or ten about stocks that could be bought (or sold) early the next year in order to keep that commission flow going (and from the broker's perspective hopefully building). It seemed to me that the ideas took a very simple form: buy the underperformers and sell the outperformers. Well who does not like a bargain or - indeed - to take profits? So from an akin premise - but with an added slice of cynicism (and no need to elicit your brokerage commission flows!) - what does a 'brokerage lunch list' throw up as interesting in December 2018 looking ahead into 2019?...
Much has been said or written about GlaxoSmithKline (GSK) during 2018 and my most recent contribution back in July suggested that a divisional split-up was a spoof. Well today's announcement that Glaxo has formed a joint venture vehicle with US pharma behemoth Pfizer for their respective consumer health arms (with ownership split 68%/32% in favour of Glaxo) appears at face value like a step in the right direction for under pressure CEO Emma Walmsley and team…
Hello, Share Pinchers. One of the most attractive sectors to invest in for those who like to inhabit the moral high ground is medicine. Who would not want to try to alleviate pain and suffering in Britain and the world? Yes, there can be worries that some companies are not as good as they might be in curbing the costs of treatment and drugs, but on the whole it’s a satisfying area of investment.
I know the summer heat is starting to get to everyone but today's regulatory and brokerage output is a little...coy on a few names I have written about in the past few months. So in the spirit of helping market transparency...here is what three large corporate names are trying to say...
Hello, Share Nappers. It was a long time ago that I sold them, but shares in Oxford BioMedica (OXB) have started doing rather well. And that is becoming more unusual for small pharmaceutical companies. So the firm must be doing something right.
Last week I hoped that GlaxoSmithKline's (GSK) backing away from a mega deal which would have seen them splurge US$20bn odd on the consumer unit of American pharma name Pfizer was an early sign of a new commitment to not building an empire and maybe even considering splitting the company up into its constituent parts. Well that slammed that door closed today with news that they are buying out the shares in a consumer healthcare jv they have with the Swiss pharma giant Novartis for a cool US$13 billion.
I was hoping for a big bit of volatility in shares in Next (NXT) today but its full year update is - in the wider scheme of things - pretty worthy. Why?
Warren Buffett always tells us that his intended investment holding period is forever, that he buys stocks he would be happy to hold if the market closed down for five years. I guess, then, if you’re Warren Buffett then the market travails of the last few days won’t bother you. If you’re not Mr Buffett I offer a few thoughts.
The big pharmaceutical companies have traditionally been a fairly safe bet for a steady source of income over the years, and through the peaks and troughs in the markets.
Hello, Share Spooners. Given the ageing and less healthy world population, I have often said that the big pharmaceuticals offer a buying opportunity. But as usual with medical advances, progress has been slow. I hold shares in GlaxoSmithKline (GSK). But although I’ve often been tempted to dive into its big rival AstraZeneca (AZN), I have resisted the urge. Now I’m rather glad I did.
Hello Share Shapers. Every so often I look at that great British pharmaceutical giant, GlaxoSmithKline (GSK) and I usually notch it up as a buy. Despite the fact that it has not been quite as successful a punt as I had hoped, I am still well up on my three year old purchase. The dividend, which I have at nearly 5% is also useful. And I was gratified that it was one of the perkiest Footsie risers on Friday.
Hello Share Punchers. I’ve just heard on the BBC more woes facing British hospitals. It does seem that most of them now have no slack and routine operations keep being put off, with nowhere to send many patients once beyond the surgeon’s knife.
You want your share tip of the year to have the potential to double or treble. You will not get that with GlaxoSmithKline (GSK). Equally it is incredibly unlikely that you might lose 75% of your cash on Glaxo. Elephants do not gallop eith forwards or backwards. My third tip of the year is a stock that could lose 75% and become a cash shell. But it is also one that could easily treble and I think he odds are on the treble not the collapse. I refer to Wishbone Gold (WSBN)
It is great to see that one of the UK's largest companies, GlaxoSmithKline (GSK) has a new CEO who has a cracking CV and and has without doubt been appointed on merit. Oh... and she wears a skirt, that is to say that she is a woman, Emma Walmsley. I wish her well. Emma demonstrates a couple of things which will horrify the liberal left.
Hello Share Pitchers. My parents were so frightened of cancer that they refused to utter the word. As a result I had never even heard of the affliction until I was an advanced teenager. These days we all still fear the condition, but we perhaps should not do so as much as we used to. This is because treatments are becoming more effective year on year. It is still an appalling killer, though.
With uncertainty over Brexit and possible market turmoil around this event, and assuming you’re not planning to move to cash, now would seem like a good time to add some defensive shares to your portfolio.
Hello Share Shiners. All right, this is another article on a promising bio science outfit. Yes, my support for companies which push through the frontiers of medicine is undiminished in 2016.
I hope you have a happy and healthy New Year. Though, especially if you are of a certain age, I fear the odds are against it. My Christmas cards usually contain letters from old friends and relatives. And I was shocked to learn that one of them had almost lost her sight, another is on crutches awaiting knee transplants, another has breast cancer and so on.
Hello Share Trippers. Oh dear! The price of crude oil drops to less than 40 dollars a barrel.That’s really nasty and we can blame OPEC for refusing to cut down on the amber nectar it has for sale.
Hello Share Surfers. The old Footsie fell 2.5% on a day which began rather well. Why? Well, according to the media, the European Central Bank 'failed to deliver on market expectations for an increase in monthly asset purchases.’
The recent big drops in many leading stock market indices, including the FTSE100, is giving an opportunity to pick some stocks up at a bargain price. I think that GlaxoSmithKline (GSK) definitely falls into that category and its current share price of around 1285p – the lowest levels since mid-2011 – offers a great long term buying opportunity for this FTSE100 listed pharmaceutical company.
If you want to make money in large cap shares then you have to spot the big changes. Deals can be such transforming events…and updates from two big FTSE-100 heavyweights over the last day or so are noteworthy.
Richard Burrows, the chairman of British American Tobacco (BATS), has increased his ownership of the company with a significant £176,017 purchase. 5,000 shares were bought at a price of 3520.34. He now has 15,000 shares in the business.
After some careful thought I have selected GlaxoSmithKline (GSK) as one of just two of my Prime Share Selections for 2015. Being honest, I find it difficult to pick two which really should be the best of all shares, but I am fairly confident GlaxoSmithKline will perform well in 2015.
Shares can be a real rollercoaster ride. ‘Mr Market’ can perform such gyrations for no logical reason, but this can still have a serious effect on our wealth. This week £62 billion was added to the value of the FTSE 100, as the index enjoyed its best week in three years.
I’ve already mentioned how the FTSE dropped a whopping 2.49% on Friday. I’ll be directly honest with you now, it was quite painful to watch. Sometimes owning shares is like living in a surreal dream, sometimes it’s like experiencing a nightmare. It’s hard to comprehend how you can be worth so much less at the end of the day... for doing nothing.
GlaxoSmithKline (GSK) has recently announced that it has failed to sell its established products portfolio. This is basically a bunch of North American and European drugs that have recently lost their patent protection.
Hello Share Samurai. There's a growing case for turning Japanese. I mean in the buying of Oriental shares.
I’m writing this article mainly for people who haven’t invested in shares yet, or those who haven’t put much of their wealth into equities. This year has been quite a buying spree for me... as of now over two thirds of my total worth is in shares, and around 75% of my quickly accessible wealth.
I’m sorry it’s been a while that I’ve written. I have been doing lots of other things, mainly to get more money to invest in shares, but I still should have written more. I’ve been doing lots of ‘active research’ including travelling to shareholders meeting and more ‘in depth’ personal research into companies that I own, but that’s still no excuse. I’ve kind of had a bit of ‘writers block’ but there’s something interesting on my mind now which hopefully I can express.
Hello Share Shapers. They say that it's the payment of dividends, rather than striking it lucky occasionally, that leads to making real money on the Stock Exchange.
It’s been a torrid year for GlaxoSmithKline’s (GSK) share price. From a year high of 1706p, it recently fell to a low of 1296.p. However there was some much needed cheer yesterday, when the shares, trading at around 1330p, were lifted to over 1400p briefly, before closing at 1385.5p. The catalyst? Publication of its results at 12 o’clock which beat expectations.
It is good to see the FTSE 100 rise today, but not all companies are joining in on the fun. Shares in British American Tobacco (BATS) have fallen, so have shares in GlaxoSmithKline (GSK) and Banco Santander (BNC) shares are basically flat at 549p.
Ebola is certainly everywhere on the news at the moment. The epidemic continues to spread like wildfire, and more people are dying all the time. Thankfully, GlaxoSmithKline (GSK) is continuing its work on a vaccine which should help stem the spread. Today it issued a press statement, opening with the following:
The FTSE took quite a hit yesterday. It closed down by 1.04% at 6495.58. Yet there is good news- I believe there are a number of buying opportunities around at the moment! For the long term investor a general market sell off should be viewed as an opportunity not a cause for alarm. So here are two stocks that I am nowlooking to add to thanks to the market wobble.
Peter Lynch makes an obvious but interesting point about the PE ratio of shares in his classic One Up on Wall Street. “If you buy back shares in a company selling at two times earnings (a p/e of 2), you will earn back your initial investment in two years, but in a company selling at 40 times earnings (a p/e of 40) it would take forty years to accomplish the same thing. Cher might be a great-grandmother by then. With all the low p/e opportunities around, why would anybody buy a stock with a high p/e?”
GlaxoSmithKline (GSK) shares are currently trading at 1457p on a PE of 13.1 and a dividend yield of 5.35%. I’ve only fairly recently bought into the company, here is a table at between 1379p and 1556.6p, So I am not exactly quids in yet but this is a long term play.
Hello Share Collectors: There is a growing case for investing in companies, which sell or look for medical cures. I think the big British pharma companies are undervalued and worth a punt.
The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self. Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that “there will always be a Glaxo”; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?
Malcolm Stacey is a very good man. He is an ethical operator in every way. But when looking at the nest of snakes that is AIM that is not perhaps the greatest attribute an investor can have. The Vipers lure you with a line about ethical investing but 99% of the time it is just so much cock.